TAREQ ABUASAB to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications TAREQ ABUASAB has written about Leukemia, Myeloid, Acute.
Connection Strength
0.753
-
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract. 2024 Dec; 20(12):1637-1644.
Score: 0.156
-
BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma. 2024 Sep; 65(9):1344-1349.
Score: 0.154
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286.
Score: 0.152
-
Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica. 2024 01 01; 109(1):293-297.
Score: 0.150
-
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56.
Score: 0.140